Compare Fortinet Inc (FTNT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs Twist Bioscience Corp — how do they compare? Fortinet Inc trades at $161.4 (market cap $118.78B), while Twist Bioscience Corp trades at $125.28 (market cap $7.72B). The key difference: Fortinet Inc is far larger — about 15.4× Twist Bioscience Corp's market cap. Which is the better fit depends on your goals.
| FTNT | TWST | |
|---|---|---|
Market Cap | $118.78B | $7.72B |
Sector | Technology | Health |
52-Week High | $168.29 | $124.88 |
52-Week Low | $75.23 | $24.16 |
Enterprise Value | $115.21B | $7.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $164.21, up 2.86% in the last session, reflecting strong momentum as it approaches its consensus price target of $174.50. The stock exhibits bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $0.90 versus $0.746 expected. Revenue growth remains robust, climbing to $6.80 billion in 2025, with a net income margin of 28.17%. Recent news highlights AI-driven cybersecurity demand as a key growth catalyst.
The outlook is positive, supported by solid fundamentals and analyst optimism, though elevated valuation ratios like a P/E of 57.2 pose risks. Competition and market volatility are concerns, but institutional buying and bullish ratings suggest further upside potential.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
